HK Stock Market Move | TYK MEDICINES-B(02410) rose by over 3%. Positive clinical data on multiple CDK inhibitors including TYK-00540 will be announced at the ESMO 2025 conference.

TYK MEDICINES-B (02410) rose by more than 3%, as of the time of this report, it was up 2.24% to 15.53 Hong Kong dollars, with a trading volume of 5.2104 million Hong Kong dollars. On the news front, on October 21, TYK MEDICINES-B announced that the company's board of directors happily disclosed the early clinical research results of three drugs TYK-00540 (CDK2/4i), TY-2699a (CDK7i), and TY-302 (CDK4/6i) in the field of cyclin-dependent protein kinase inhibitors at the European Society for Medical Oncology (ESMO) conference in the form of posters. The ESMO 2025 conference was held in Berlin, Germany from October 17-21, 2025. As one of the most influential academic events in the global oncology field, the ESMO conference attracted numerous top experts and scholars in the field, providing a platform for discussing clinical challenges and sharing cutting-edge advancements.